BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sun J, Wang Z, Ma S, Zeng G, Zhou Z, Luo K, Hou J. Clinical and virological characteristics of lamivudine resistance in chronic hepatitis B patients: A single center experience. J Med Virol 2005;75:391-8. [DOI: 10.1002/jmv.20281] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Umeoka F, Iwasaki Y, Matsumura M, Takaki A, Kobashi H, Tatsukawa M, Shiraha H, Fujioka S, Sakaguchi K, Shiratori Y. Early detection and quantification of lamivudine-resistant hepatitis B virus mutants by fluorescent biprobe hybridization assay in lamivudine-treated patients. J Gastroenterol 2006;41:693-701. [PMID: 16933008 DOI: 10.1007/s00535-006-1834-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
2 Li P, Geng J, Li W, Xu X, Zhang X, Zheng W, Yu Y, Yang Z, Wang M. Antiviral efficacy of entecavir for hepatitis B virus rtA181V/T mutants. Virol J 2017;14:68. [PMID: 28376852 DOI: 10.1186/s12985-017-0739-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
3 Yu Z, Wang Z, Chen J, Li H, Lin Z, Zhang F, Zhou Y, Hou J. GTPase activity is not essential for the interferon-inducible MxA protein to inhibit the replication of hepatitis B virus. Arch Virol. 2008;153:1677-1684. [PMID: 18668195 DOI: 10.1007/s00705-008-0168-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
4 Osiowy C, Villeneuve JP, Heathcote EJ, Giles E, Borlang J. Detection of rtN236T and rtA181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2). J Clin Microbiol. 2006;44:1994-1997. [PMID: 16757589 DOI: 10.1128/jcm.02477-05] [Cited by in Crossref: 52] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
5 Murata M, Furusyo N, Unno M, Ogawa E, Toyoda K, Taniai H, Ohnishi H, Hayashi J. Long-term effects of lamivudine treatment in Japanese chronic hepatitis B patients. World J Gastroenterol 2011; 17(24): 2945-2952 [PMID: 21734806 DOI: 10.3748/wjg.v17.i24.2945] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
6 Li W, Deng R, Liu S, Wang K, Sun J. Hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy: The emerging role of non-viral risk factors. Liver Int 2020;40:2316-25. [PMID: 32666675 DOI: 10.1111/liv.14607] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
7 Leemans W, Janssen H, de Man R. Future prospectives for the management of chronic hepatitis B. World J Gastroenterol 2007; 13(18): 2554-2567 [PMID: 17552002 DOI: 10.3748/wjg.v13.i18.2554] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 22] [Article Influence: 1.1] [Reference Citation Analysis]
8 Alvarado-Esquivel C, de la Ascensión Carrera-Gracia M, Conde-González CJ, Juárez-Figueroa L, Ruiz-Maya L, Aguilar-Benavides S, Torres-Valenzuela A, Sablon E. Genotypic resistance to lamivudine among hepatitis B virus isolates in Mexico. J Antimicrob Chemother. 2006;57:221-223. [PMID: 16373428 DOI: 10.1093/jac/dki457] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
9 Chen LY, Huang J, Zhang XP, Qiao P, Zhang W, Yang NM, Liu HJ, Geng YY, Qiu JM, Wang SQ. Clinical evaluation of oligonucleotide microarrays for the detection of HBV mutants associated with lamivudine resistance. Pharmacogenomics. 2005;6:721-730. [PMID: 16207149 DOI: 10.2217/14622416.6.7.721] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
10 Hatakeyama T, Noguchi C, Hiraga N, Mori N, Tsuge M, Imamura M, Takahashi S, Kawakami Y, Fujimoto Y, Ochi H, Abe H, Maekawa T, Kawakami H, Yatsuji H, Aisaka Y, Kohno H, Aimitsu S, Chayama K. Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine. Hepatology. 2007;45:1179-1186. [PMID: 17465002 DOI: 10.1002/hep.21581] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 3.1] [Reference Citation Analysis]
11 França P, Coelho H, Brandão C, Segadas J, Quintaes R, Carrilho F, Ono-nita S, Mattos A, Tovo C, Gouvea V, Sablon E, Vanderborght B. The emergence of YMDD mutants precedes biochemical flare by 19 weeks in lamivudine-treated chronic hepatitis B patients: an opportunity for therapy reevaluation. Braz J Med Biol Res 2007;40:1605-14. [DOI: 10.1590/s0100-879x2006005000169] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
12 Wang XL, Xie SG, Zhang L, Yang WX, Wang X, Jin HZ. Comparison of ligase detection reaction and real-time PCR for detection of low abundant YMDD mutants in patients with chronic hepatitis B. World J Gastroenterol 2008; 14(1): 120-124 [PMID: 18176973 DOI: 10.3748/wjg.14.120] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
13 Kobayashi M, Suzuki F, Akuta N, Suzuki Y, Arase Y, Ikeda K, Hosaka T, Sezaki H, Kobayashi M, Iwasaki S. Response to long-term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C. J Med Virol. 2006;78:1276-1283. [PMID: 16927289 DOI: 10.1002/jmv.20701] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
14 Wang Z, Huang Y, Wen S, Zhou B, Hou J. Hepatitis B virus genotypes and subgenotypes in China. Hepatol Res 2007;37:S36-41. [PMID: 17627634 DOI: 10.1111/j.1872-034X.2007.00102.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 18] [Article Influence: 4.7] [Reference Citation Analysis]
15 Kim JH, Yu SK, Seo YS, Yim HJ, Yeon JE, Park JJ, Kim JS, Bak YT, Lee CH, Byun KS. Clinical outcomes of chronic hepatitis B patients with persistently detectable serum hepatitis B virus DNA during lamivudine therapy. J Gastroenterol Hepatol 2007;22:1220-5. [PMID: 17532786 DOI: 10.1111/j.1440-1746.2007.04921.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
16 Akman SA, Kose S, Halicioglu O. Lamivudine and adefovir resistance in children and young adults with chronic hepatitis B. Int J Infect Dis. 2010;14:e236-e239. [PMID: 19665408 DOI: 10.1016/j.ijid.2009.04.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
17 Wang J, Zhou B, Lai Q, Wang Y, Shen G, Wang Z, Chen J, Hou J. Clinical and virological characteristics of chronic hepatitis B with concurrent hepatitis B E antigen and antibody detection: Concurrent circulation of HBeAg and anti-Hbe. Journal of Viral Hepatitis 2011;18:646-52. [DOI: 10.1111/j.1365-2893.2010.01345.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
18 Yıldız O, Aygen B, Demirtürk N, Demirdal T, Inan D, Yıldırmak T, Kantürk A, Tütüncü E, Group HBS. Lamivudine resistance mutations in patients infected with hepatitis B virus genotype D. World J Gastroenterol 2011; 17(45): 4987-4992 [PMID: 22174548 DOI: 10.3748/wjg.v17.i45.4987] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
19 Xu WZ, Fang Y, Li D, Wang Y, Shang QL, Li GQ, Teng X, Gu HX. Construction and expression of eukaryotic plasmids containing lamivudine-resistant or wild-type strains of Hepatitis B Virus genotype C. World J Gastroenterol 2008; 14(23): 3733-3738 [PMID: 18595141 DOI: 10.3748/wjg.14.3733] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
20 Pan XP, Li LJ, Du WB, Li MW, Cao HC, Sheng JF. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C. J Viral Hepat. 2007;14:767-77. [PMID: 17927612 DOI: 10.1111/j.1365-2893.2007.00869.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
21 Yang ZJ, Tu MZ, Liu J, Wang XL, Jin HZ. Comparison of amplicon-sequencing, pyrosequencing and real-time PCR for detection of YMDD mutants in patients with chronic hepatitis B. World J Gastroenterol 2006; 12(44): 7192-7196 [PMID: 17131486 DOI: 10.3748/wjg.v12.i44.7192] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]